Welcome to our dedicated page for Akoya Biosciences news (Ticker: AKYA), a resource for investors and traders seeking the latest updates and insights on Akoya Biosciences stock.
Akoya Biosciences, Inc. (AKYA), known as The Spatial Biology Company®, generates news that spans technology developments, collaborations, financial reporting, and corporate transactions. Company announcements emphasize its single-cell imaging and spatial proteomics platforms, which are used to phenotype cells with spatial context and study how they organize and interact in disease. News items often describe how Akoya’s PhenoCode™ Panels, PhenoCycler®, Phenor® Fusion, and Phenor HT instruments are applied across discovery, translational, and clinical research.
Investors and researchers following AKYA-related news will find updates on spatial biology and proteomics initiatives, including large-scale projects and partnerships. Recent releases highlight collaborations such as the Cancer Grand Challenges-funded study using PhenoCycler-Fusion, the SUPER study with the Singapore Translational Cancer Consortium leveraging the IO60 panel to investigate PD-1 immunotherapy response, and the Enable Medicine Pan-Cancer Atlas built on Akoya’s PhenoCycler-Fusion and IO60 technologies. These stories illustrate how Akoya’s platforms are integrated into biomarker discovery, drug development, and precision oncology efforts.
News coverage has also included financial results and operational updates, such as quarterly revenue composition, changes in operating expenses, and growth in the installed base of instruments and publications citing Akoya’s technology. In addition, corporate and capital markets news has been prominent, particularly the Amended and Restated Agreement and Plan of Merger with Quanterix Corporation and subsequent shareholder and activist responses to that transaction.
Following the completion of the merger on July 8, 2025, Akoya became a wholly owned subsidiary of Quanterix, and its common stock was removed from listing on Nasdaq. The AKYA news stream therefore serves as a historical archive of Akoya’s activities as an independent public company, covering its evolution in spatial biology, its collaborations, and the steps leading to its acquisition by Quanterix.
Akoya Biosciences and NeraCare have entered an exclusive agreement to enhance personalized therapy selection for early-stage melanoma patients. The partnership aims to combine Akoya's PhenoImager HT platform with NeraCare's Immunoprint test to improve access to life-saving therapies for melanoma patients, addressing the critical unmet medical need to identify at-risk patients. The collaboration leverages NeraCare's robust clinical data and Immunoprint's ability to identify high-risk patients, potentially revolutionizing treatment options for early-stage melanoma.
Akoya Biosciences, Inc. has opened its Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts to meet the increasing demand for its spatial biology solutions. The facility aims to drive operational efficiencies, enhance customer service, and expand the company's portfolio. The 32,000 square foot facility includes R&D, manufacturing, quality control, warehouse space, and distribution, emphasizing cross-functional collaboration and faster product development.
Akoya Biosciences and Shanghai KR Pharmtech have announced that KR-HT5, developed using Akoya's PhenoImager HT technology, has received premarket approval from China's NMPA. This approval will support next generation pathology clinical workflows in China, providing clinicians with a high-throughput platform for multiplex biomarker analysis. Shanghai KR Pharmtech will offer KR-HT5 as part of its Next Generation Pathology solutions.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.